Gabapentin (All indications) updated on 04-22-2025

Psychomotor developmental disorders/delay

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S19340
R82015		 Moore (Controls exposed to LTG) (Indication NOS), 2025 Gross motor disorders - Assessment offered to all children - At the 27–30 months during pregnancy (anytime or not specified) population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 1.48 [0.97;2.24] C
excluded (control group) 		63/1,128   36/934 99 1,128
ref
S19334
R82034		 Moore (Controls unexposed, general pop) (Indication NOS), 2025 Fine motor disorders - Assessment offered to all children - At the 27–30 months during pregnancy (anytime or not specified) population based cohort retrospective unexposed (general population or NOS) Adjustment: No Matched 2.74 [2.14;3.50] C 87/1,128   334/11,276 421 1,128
ref
Total 1 studies 2.74 [2.14;3.50] 421 1,128
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Moore (Controls unexposed, general pop) (Indication NOS), 2025Moore, 2025 1 2.74[2.14; 3.50]4211,1280%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: low0.910.01.0ROB: A: confounding, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, general pop) (Indication NOS;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 2.74[2.14; 3.50]4211,128 -NAMoore (Controls unexposed, general pop) (Indication NOS), 2025 1 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 2.74[2.14; 3.50]4211,128 -NAMoore (Controls unexposed, general pop) (Indication NOS), 2025 1 Tags Adjustment   - No  - No 2.74[2.14; 3.50]4211,128 -NAMoore (Controls unexposed, general pop) (Indication NOS), 2025 1 MatchedMatched 2.74[2.14; 3.50]4211,128 -NAMoore (Controls unexposed, general pop) (Indication NOS), 2025 1 All studiesAll studies 2.74[2.14; 3.50]4211,128 -NAMoore (Controls unexposed, general pop) (Indication NOS), 2025 10.510.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 19340

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 2.74[2.14; 3.50]4211,128 -NAMoore (Controls unexposed, general pop) (Indication NOS), 2025 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.48[0.97; 2.24]991,128 -NAMoore (Controls exposed to LTG) (Indication NOS), 2025 10.510.01.0

Umbrella review (other published meta-analyses)

Published MAControlPeriodTE95% CIn exposedkI2 Veroniki b (NMA) (Psychomotor Developmental Delay)Veroniki b (NMA) (Psychomotor Developmental Delay) 9.03[1.00; 62.78]NA-Wwhatever (meta-analysis)Anyduring pregnancy (anytime or not specified)studies TTT-9 metaPregmetaPreg 2.74[2.14; 3.50]NaN%1,128----Moore (Controls unexposed, general pop) (Indication NOS), 2025 10.510.01.0